BACKGROUND: When a clinical treatment fails or shows suboptimal results, the question of when to switch to another treatment arises. Treatment switching strategies are often dynamic because the time of switching depends on the evolution of an individual's time-varying covariates. Dynamic strategies can be directly compared in randomized trials. For example, HIV-infected individuals receiving antiretroviral therapy could be randomized to switching therapy within 90 days of HIV-1 RNA crossing above a threshold of either 400 copies/ml (tight-control strategy) or 1000 copies/ml (loose-control strategy).METHODS: We review an approach to emulate a randomized trial of dynamic switching strategies using observational data from the Antiretroviral Th...
The current goal of initial antiretroviral (ARV) therapy is suppression of plasma human immunodefici...
BACKGROUND: UNAIDS models use data from the International epidemiology Databases to Evaluate AIDS (I...
Although combination antiretroviral therapy continues to evolve, with potentially more effective opt...
BACKGROUND: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Background: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Supplemental Digital Content is Available in the Text. To illustrate an approach to compare CD4 cell...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
Optimal timing of initiating antiretroviral therapy has been a controversial topic in HIV research. ...
Background: UNAIDS models use data from the International epidemiology Databases to Evaluate AIDS (I...
Modeling clinical endpoints as a function of change in antiretroviral therapy (ART) attempts to answ...
Traditional epidemiologic approaches allow us to compare counterfactual outcomes under 2 exposure di...
BACKGROUND: Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-posi...
The current goal of initial antiretroviral (ARV) therapy is suppression of plasma human immunodefici...
BACKGROUND: UNAIDS models use data from the International epidemiology Databases to Evaluate AIDS (I...
Although combination antiretroviral therapy continues to evolve, with potentially more effective opt...
BACKGROUND: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Background: When a clinical treatment fails or shows suboptimal results, the question of when to swi...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Decisions about when to start or switch a therapy often depend on the frequency with which individua...
Supplemental Digital Content is Available in the Text. To illustrate an approach to compare CD4 cell...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
Optimal timing of initiating antiretroviral therapy has been a controversial topic in HIV research. ...
Background: UNAIDS models use data from the International epidemiology Databases to Evaluate AIDS (I...
Modeling clinical endpoints as a function of change in antiretroviral therapy (ART) attempts to answ...
Traditional epidemiologic approaches allow us to compare counterfactual outcomes under 2 exposure di...
BACKGROUND: Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-posi...
The current goal of initial antiretroviral (ARV) therapy is suppression of plasma human immunodefici...
BACKGROUND: UNAIDS models use data from the International epidemiology Databases to Evaluate AIDS (I...
Although combination antiretroviral therapy continues to evolve, with potentially more effective opt...